Literature DB >> 30850267

Evaluation of age of death in Niemann-Pick disease, type C: Utility of disease support group websites to understand natural history.

Simona E Bianconi1, Dylan I Hammond1, Nicole Y Farhat1, An Dang Do1, Kisha Jenkins1, Antony Cougnoux1, Kyle Martin1, Forbes D Porter2.   

Abstract

Niemann-Pick disease, type C (NPC) is a neurodegenerative lysosomal storage disease affecting the visceral organs and the central nervous system. The age of initial presentation varies from fetal to adult onset, although childhood onset is most common. The life expectancy for the full spectrum of NPC patients is not well defined, and it is unknown if current supportive care impacts the natural history. In order to assess age of death for a large cohort of NPC patients, we "crowd-sourced" age and year of death from information posted on disease support group website memorial walls. We analyzed data from 338 individuals who died between 1968 and 2018. In addition to age of death, gender can be inferred from given names and photographs. The median age of death was 13 years with a range from 0.1-69 years. Although sex significantly affects survival of NPC1 mutant mice, we did not observe a gender dependent survival difference in NPC patients. Median age of survival across time increased between the earliest patients and the most recently deceased patient; however, we found no significant change in survival over the last 20 years. These data suggest that supportive medical care has not impacted survival in the recent past and provides support for the use of historic controls in evaluating therapeutic interventions. Published by Elsevier Inc.

Entities:  

Keywords:  Lysosomal storage disease; NPC; Niemann-Pick disease, type C

Mesh:

Year:  2019        PMID: 30850267      PMCID: PMC6535124          DOI: 10.1016/j.ymgme.2019.02.004

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  17 in total

1.  Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C.

Authors:  Nicole M Yanjanin; Jorge I Vélez; Andrea Gropman; Kelly King; Simona E Bianconi; Sandra K Conley; Carmen C Brewer; Beth Solomon; William J Pavan; Mauricio Arcos-Burgos; Marc C Patterson; Forbes D Porter
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-01-05       Impact factor: 3.568

2.  Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol.

Authors:  Hyock Joo Kwon; Lina Abi-Mosleh; Michael L Wang; Johann Deisenhofer; Joseph L Goldstein; Michael S Brown; Rodney E Infante
Journal:  Cell       Date:  2009-06-26       Impact factor: 41.582

3.  Identification of HE1 as the second gene of Niemann-Pick C disease.

Authors:  S Naureckiene; D E Sleat; H Lackland; A Fensom; M T Vanier; R Wattiaux; M Jadot; P Lobel
Journal:  Science       Date:  2000-12-22       Impact factor: 47.728

Review 4.  Niemann-Pick disease type C.

Authors:  M T Vanier; G Millat
Journal:  Clin Genet       Date:  2003-10       Impact factor: 4.438

Review 5.  Niemann-Pick disease type C.

Authors:  Marie T Vanier
Journal:  Orphanet J Rare Dis       Date:  2010-06-03       Impact factor: 4.123

6.  Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study.

Authors:  Marc C Patterson; Darleen Vecchio; Helena Prady; Larry Abel; James E Wraith
Journal:  Lancet Neurol       Date:  2007-09       Impact factor: 44.182

7.  NPC-db, a Niemann-Pick type C disease gene variation database.

Authors:  Heiko Runz; Dirk Dolle; Anna Melissa Schlitter; Johannes Zschocke
Journal:  Hum Mutat       Date:  2008-03       Impact factor: 4.878

8.  Observational, retrospective study of a large cohort of patients with Niemann-Pick disease type C in the Czech Republic: a surprisingly stable diagnostic rate spanning almost 40 years.

Authors:  Helena Jahnova; Lenka Dvorakova; Hana Vlaskova; Helena Hulkova; Helena Poupetova; Martin Hrebicek; Pavel Jesina
Journal:  Orphanet J Rare Dis       Date:  2014-09-19       Impact factor: 4.123

Review 9.  Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: systematic literature review and evidence from studies with miglustat.

Authors:  Mark Walterfang; Yin-Hsiu Chien; Jackie Imrie; Derren Rushton; Danielle Schubiger; Marc C Patterson
Journal:  Orphanet J Rare Dis       Date:  2012-10-06       Impact factor: 4.123

10.  High incidence of unrecognized visceral/neurological late-onset Niemann-Pick disease, type C1, predicted by analysis of massively parallel sequencing data sets.

Authors:  Christopher A Wassif; Joanna L Cross; James Iben; Luis Sanchez-Pulido; Antony Cougnoux; Frances M Platt; Daniel S Ory; Chris P Ponting; Joan E Bailey-Wilson; Leslie G Biesecker; Forbes D Porter
Journal:  Genet Med       Date:  2015-03-12       Impact factor: 8.822

View more
  11 in total

1.  Reduction of glutamate neurotoxicity: A novel therapeutic approach for Niemann-Pick disease, type C1.

Authors:  Antony Cougnoux; Julia C Yerger; Mason Fellmeth; Jenny Serra-Vinardell; Fatemeh Navid; Christopher A Wassif; Niamh X Cawley; Forbes D Porter
Journal:  Mol Genet Metab       Date:  2021-11-16       Impact factor: 4.797

2.  Cost-effectiveness of miglustat versus symptomatic therapy of Niemann-Pick disease type C.

Authors:  Medo Gutić; Miloš N Milosavljević; Slobodan M Janković
Journal:  Int J Clin Pharm       Date:  2022-10-15

3.  The CD22-IGF2R interaction is a therapeutic target for microglial lysosome dysfunction in Niemann-Pick type C.

Authors:  John V Pluvinage; Jerry Sun; Christel Claes; Ryan A Flynn; Michael S Haney; Tal Iram; Xiangling Meng; Rachel Lindemann; Nicholas M Riley; Emma Danhash; Jean Paul Chadarevian; Emma Tapp; David Gate; Sravani Kondapavulur; Inma Cobos; Sundari Chetty; Anca M Pașca; Sergiu P Pașca; Elizabeth Berry-Kravis; Carolyn R Bertozzi; Mathew Blurton-Jones; Tony Wyss-Coray
Journal:  Sci Transl Med       Date:  2021-12-01       Impact factor: 19.319

4.  Maternal immune activation modifies the course of Niemann-pick disease, type C1 in a gender specific manner.

Authors:  Antony Cougnoux; Mason Fellmeth; Tansy Gu; Cristin D Davidson; Alana L Gibson; William J Pavan; Forbes D Porter
Journal:  Mol Genet Metab       Date:  2019-10-17       Impact factor: 4.797

5.  Quantitating the epigenetic transformation contributing to cholesterol homeostasis using Gaussian process.

Authors:  Chao Wang; Samantha M Scott; Kanagaraj Subramanian; Salvatore Loguercio; Pei Zhao; Darren M Hutt; Nicole Y Farhat; Forbes D Porter; William E Balch
Journal:  Nat Commun       Date:  2019-11-07       Impact factor: 14.919

6.  Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: A large retrospective observational study.

Authors:  Marc C Patterson; William S Garver; Robert Giugliani; Jackie Imrie; Helena Jahnova; F John Meaney; Yann Nadjar; Marie T Vanier; Patrick Moneuse; Olivier Morand; Daniel Rosenberg; Barbara Schwierin; Benedicte Héron
Journal:  J Inherit Metab Dis       Date:  2020-05-08       Impact factor: 4.982

Review 7.  Understanding and Treating Niemann-Pick Type C Disease: Models Matter.

Authors:  Valentina Pallottini; Frank W Pfrieger
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

8.  Individualized management of genetic diversity in Niemann-Pick C1 through modulation of the Hsp70 chaperone system.

Authors:  Chao Wang; Samantha M Scott; Shuhong Sun; Pei Zhao; Darren M Hutt; Hao Shao; Jason E Gestwicki; William E Balch
Journal:  Hum Mol Genet       Date:  2020-01-01       Impact factor: 5.121

9.  Evaluation of the Potential Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Niemann-Pick Disease, Type C1.

Authors:  Niamh X Cawley; Anna T Lyons; Daniel Abebe; Christopher A Wassif; Forbes D Porter
Journal:  Int J Mol Sci       Date:  2020-03-31       Impact factor: 5.923

10.  Gender-Specific Effects of Two Treatment Strategies in a Mouse Model of Niemann-Pick Disease Type C1.

Authors:  Carsten Holzmann; Martin Witt; Arndt Rolfs; Veronica Antipova; Andreas Wree
Journal:  Int J Mol Sci       Date:  2021-03-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.